Data: ATSP-7041 as first-in-class p53 pathway re-activator for solid, hematologic cancers
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical ...
Aug 15, 2013
0
0